comprehensive -WSS

comprehensive

author：explore 2025-10-02 01:08:21 - browse：31484

Boston Scientific headquarters -- Health coverage from STAT — Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Google and Epic fight stronger regulation of AI in health care

focus

WSS

Explaining an after

Medicare must police algorithms in Medicare Advantage, Dems say

Medicare has a new plan to address drug shortages

Prime Medicine says its gene editing passes test in monkeys

Google and Epic fight stronger regulation of AI in health care

Medicare must police algorithms in Medicare Advantage, Dems say

hotspot

comprehensive

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Medical leaders decry Supreme Court decision on affirmative action

Infant mortality in U.S. rose last year for first time in decades: CDC

Walensky prepares to leave CDC — and Congress — behind

What is microchimerism and how does it affect maternal health?

Bright Health sells Medicare Advantage business to Molina

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Medical records are filled with copy

Sarepta Duchenne therapy fails to meet primary endpoint in trial

hotspot

Medicare must police algorithms in Medicare Advantage, Dems say

Sanders adds drug shortage policies to pandemic preparedness bill

Group opposing PBM reform sets lobbying record

Travis Kelce and the trap of celebrity vaccine endorsements

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Sanofi seeks simpler, safer CRISPR sickle cell cure

hotspot

Wikipedia

focus

focus